Seikagaku and its subsidiaries are mainly engaged in the research and development, manufacture, purchase and sale of medical devices specifically related to glycoconjugates. Co. operates in two business segments. Pharmaceutical segment offers pharmaceutical products made from hyaluronic acid, a major component of glycoconjugates including joint function improving agents, ophthalmic surgical aids, surgical aids for endoscopic mucosal resection, and bulk products. Limulus amebocyte lysate ("LAL") segment offers endotoxin-detecting reagents made from LAL and other, to be used for quality control in the manufacturing process of pharmaceuticals and release test and medical devices.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...
The general evaluation of KINDER MORGAN INCO. (US), a company active in the Pipelines industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date May 26, 2020, the closing price was USD 15.80 and its potential was estimated at USD 17.78.
The independent financial analyst theScreener just requalified the general evaluation of IONIS PHARMS.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date May 26, 2020, the closing price was USD 56.04 and its target price was estimated at USD 43.76.
The independent financial analyst theScreener just awarded an improved star rating to INTERPUBLIC GP.OF COS. (US), active in the Media Agencies industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 3 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date May 26, 2020, the closing price was USD 17.53 and its expected value was estimated at USD 16.36.
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.